Each month, join Kashef Qaadri, a biologist turned bioinformatician, as he interviews guests exploring real-world research informatics challenges through use-cases, providing insights and strategies for integrating and analyzing complex data that are driving BioPharma R&D.
All content for BioRad.io is the property of Bio-Rad Laboratories, Inc. and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Each month, join Kashef Qaadri, a biologist turned bioinformatician, as he interviews guests exploring real-world research informatics challenges through use-cases, providing insights and strategies for integrating and analyzing complex data that are driving BioPharma R&D.
Episode 17: Biomarker Identification for Early Disease Detection
BioRad.io
30 minutes 15 seconds
2 years ago
Episode 17: Biomarker Identification for Early Disease Detection
Episode 17: Biomarker Identification for Early Disease DetectionWhen diseases such as cancers are detected in their early stages, before they have spread, the overall survival rate is significantly higher than when diagnosed in later stages. Developing biomarker tests that detect early-stage tumors is complex and difficult, but quite rewarding, leading to improved characterization, treatment, and management of cancer. Determining which types of data (genomic, proteomic, etc.) are most informative is a major challenge requiring extensive research and discovery. In this episode, we discuss the need for early detection tools, methods for developing them, and some of the informatics challenges, including algorithm and model development, handling large volumes of data from multiple sources, and data integration.Guest: Peter Meintjes, PhD, CEO, Pacific Edge, Ltd.
BioRad.io
Each month, join Kashef Qaadri, a biologist turned bioinformatician, as he interviews guests exploring real-world research informatics challenges through use-cases, providing insights and strategies for integrating and analyzing complex data that are driving BioPharma R&D.